Maywufa Co Ltd (1731) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Maywufa Co Ltd TWD 15.29, price TWD 20.90, upside -26.8%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Maywufa Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan.
Show more
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. The company engages in the manufacturing, processing, and distribution of hairdressing products, soap, and cosmetics; distribution, wholesale, and retail trading of various beauty products, health products, and sports equipment; retail and wholesale business of health food, such as vitamin pills and oral liquid nutrients; trading, wholesale, and retail of medical drugs and medical equipment; wholesale and retail sales of food, baby products, and general food products; and wholesale trading and agency business. It also provides consulting and analysis; warehousing services; and mother and baby skin care products under the Mustela brand. In addition, the company provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. Maywufa Company Ltd. was incorporated in 1976 and is headquartered in Taipei, Taiwan.
Stock analysis
Maywufa Co Ltd (1731) currently trades at 20.90 TWD, while our model-based Fair Value estimate is 15.29 TWD, implying the stock looks roughly 36.7% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 23.15 TWD per share, and 5 of the 22 models we run sit above the 20.90 TWD price.
Bear case: the Earnings-Based group reads lowest at 7.14 TWD, and 17 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 10.76 TWD (bear) to 20.66 TWD (bull), the price of 20.90 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Maywufa Co Ltd reported revenue of 1.6B TWD in FY2025 versus 1.3B TWD in FY2021, a compound +5.3%/yr. Reported net income was 181M TWD in FY2025, compounding +2.4%/yr from FY2021.
Key figures
Market cap 2.8B TWD (≈ $87.6M) · P/E ratio 15.3 · P/S ratio 1.75 · EPS (TTM) 1.36 TWD · Dividend yield 5.8% · Net margin 11.4% · Return on equity 8.5% · Return on assets (EBIT) 7.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −27%, 1731 screens richer than that median.
Fair Value models
Bear 10.76 TWDFair Value 15.29 TWDBull 20.66 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.1024 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2020 (pandemic). Over 10 years: +1.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.0%
Dividend (yield on the price)5.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2% vs 9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 14%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +4.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 13/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside−27% · Below median
Profitability
Return on equity (TTM)8% · Above median
Return on assets4% · Above median
Net margin (TTM)12% · Above median
Operating margin (TTM)17% · Above median
Growth and dividend
Revenue growth7% · Above median
Dividend yield (TTM)5.8% · Top 25%
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)15.3× · Cheaper than median
P/B1.29× · Cheaper than median
P/S (TTM)1.72× · Cheaper than median
P/FCF0.4× · Cheapest 25%
EV/EBITDA11.5× · Cheaper than median
PEG0.36× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)36· sector 20
PAST (return on equity)34· sector 27
HEALTH (low debt)85· sector 96
DIVIDEND (yield)100· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Maywufa Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1731
Frequently asked questions
Is Maywufa Co Ltd (1731) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 15.29 TWD versus a price of 20.90 TWD, about −27% upside (overvalued).
What is the fair value of 1731?
Our model-based fair value for Maywufa Co Ltd is 15.29 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 20.90 TWD.
What is the quality score of 1731?
Maywufa Co Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Maywufa Co Ltd (1731)?
Our model-based price target is the fair value of 15.29 TWD (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 10.76 TWD, optimistic scenario 20.66 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Maywufa Co Ltd stock forecast for 2026?
Our models put fair value at 15.29 TWD, about −27% upside versus a price of 20.90 TWD (overvalued). Cautious scenario 10.76 TWD, optimistic scenario 20.66 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Maywufa Co Ltd (1731)?
Maywufa Co Ltd reported trailing-twelve-month revenue of about 1.6B TWD (latest available figure, as of Sep 24, 2026).
Does Maywufa Co Ltd pay a dividend?
Maywufa Co Ltd currently shows a dividend yield of about 5.84% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Maywufa Co Ltd (1731)?
For today's price to be fair in a discounted-cash-flow model, Maywufa Co Ltd would have to grow free cash flow by +6.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1731 use?
Our models discount Maywufa Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.09, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Maywufa Co Ltd that is +6.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Maywufa Co Ltd (1731) delivered so far?
Over the past 5 years revenue at Maywufa Co Ltd grew +8.3 % a year. The price currently implies +6.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Maywufa Co Ltd (1731) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Maywufa Co Ltd (+6.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Maywufa Co Ltd (1731)?
The free-cash-flow yield on the price is 7.57 %: that much free cash flow Maywufa Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Maywufa Co Ltd (1731)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maywufa Co Ltd it is 15.29 TWD per share (as of Sep 24, 2026), against a price of 20.90 TWD. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Maywufa Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1731 trades above its calculated fair value: price 20.90 TWD, fair value 15.29 TWD, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1731?
No. The price is what the market pays today (20.90 TWD); the fair value is what the company's own numbers justify (15.29 TWD). For Maywufa Co Ltd the two are 5.61 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Maywufa Co Ltd worth?
The market values Maywufa Co Ltd at about 2.8B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 20.90 TWD; our models calculate a fair value of 15.29 TWD per share.
What do the bullish and bearish scenarios say about 1731?
Our models span a range for Maywufa Co Ltd: cautious scenario 10.76 TWD, base 15.29 TWD, optimistic 20.66 TWD per share (as of Sep 24, 2026, price 20.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1731?
Maywufa Co Ltd trades at a price-to-earnings ratio of 15.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 15.29 TWD is built from several models across several years. Other multiples: PEG 0.4, P/B 1.3, P/S 1.7, EV/EBITDA 11.5.
What is the PEG ratio of 1731?
The PEG ratio of Maywufa Co Ltd is 0.36 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Maywufa Co Ltd (1731)?
Balance-sheet figures for Maywufa Co Ltd (as of Sep 24, 2026): return on equity 8.5%, debt of 0.29 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 1731 from its 52-week high?
Maywufa Co Ltd trades at 20.90 TWD, about 6% below its 52-week high of 22.20 TWD and 2% above the low of 20.49 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 15.29 TWD is for.
Which stocks are comparable to Maywufa Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Maywufa Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 20.90 TWD, calculated fair value 15.29 TWD (−27%), Quality Score 66/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1731 calculated?
We run Maywufa Co Ltd through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 15.29 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Maywufa Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Maywufa Co Ltd (1731)?
The closing price on Sep 24, 2026 was 20.90 TWD. Our model-based fair value is 15.29 TWD, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Maywufa Co Ltd right now?
Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (10.76 TWD to 20.66 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Maywufa Co Ltd (1731) come from?
Earnings per share at Maywufa Co Ltd grew +8.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +0.9 %, EBIT margin +6.8 %, tax rate −0.6 %, residual (interest, one-offs) +1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Maywufa Co Ltd
How large is the market capitalisation of Maywufa Co Ltd (1731)?
The market capitalisation of Maywufa Co Ltd is 2.8B TWD (≈ $87.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Maywufa Co Ltd (1731)?
The price-to-sales ratio of Maywufa Co Ltd is 1.75 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Maywufa Co Ltd (1731)?
Earnings per share at Maywufa Co Ltd are 1.36 TWD (price ÷ EPS = P/E 15.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Maywufa Co Ltd (1731)?
The dividend yield of Maywufa Co Ltd is 5.8% (payout 89.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Maywufa Co Ltd (1731)?
The net margin of Maywufa Co Ltd is 11.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Maywufa Co Ltd (1731)?
The return on equity (ROE) of Maywufa Co Ltd is 8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Maywufa Co Ltd (1731)?
On an EBIT basis the return on assets of Maywufa Co Ltd is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Maywufa Co Ltd (1731)?
The operating margin of Maywufa Co Ltd is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Maywufa Co Ltd (1731)?
Revenue at Maywufa Co Ltd is growing +7.1% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Maywufa Co Ltd (1731)?
Earnings per share at Maywufa Co Ltd are growing +7.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Maywufa Co Ltd (1731) carry?
The net debt of Maywufa Co Ltd is 417M TWD (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Maywufa Co Ltd in the live analysis
One click puts Maywufa Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
